Chemoprevention of prostate cancer: Focus on key opportunities and clinical trials

Robin Leach, Brad Pollock, Joseph Basler, Dean Troyer, Susan Naylor, Ian M Thompson

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations

Abstract

By 2004-2005, the final results of the Prostate Cancer Prevention Trial should be available. Within several years thereafter, results of the SELECT should be available. The growing list of potential agents for prostate cancer prevention continues to grow and includes COX-2 inhibitors, vitamin D, dietary interventions (soy, isoflavenoids, low-fat diet), and many others. As prospective trials are completed and molecular genetic correlations are developed, it is almost certain that specific recommendations, tailored to the individual patient, will be developed. Ultimately, through these efforts, it can be anticipated that the primary focus for control of prostate cancer will shift from early detection and treatment to prevention.

Original languageEnglish (US)
Pages (from-to)227-237
Number of pages11
JournalUrologic Clinics of North America
Volume30
Issue number2
DOIs
StatePublished - May 2003

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Chemoprevention of prostate cancer: Focus on key opportunities and clinical trials'. Together they form a unique fingerprint.

Cite this